U.S. Markets close in 56 mins

Down 25% in 2021, Is Compass Pathways Undervalued?

·4 min read
Down 25% in 2021, Is Compass Pathways Undervalued?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

To help people suffering from depression and other mental illnesses, Compass Pathways (NASDAQ: CMPS) makes psychedelic therapies based on chemicals like psilocybin. While its interventions may never be as widely used as the first-line depression treatments of today like cognitive behavioral therapy (CBT), they just might offer a source of hope. Compass' shares are down by more than 25% from the start of the year, and there's no guarantee that they'll recover.